Detalles de la búsqueda
1.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet
; 402(10408): 1133-1146, 2023 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37499670
2.
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Cancer Manag Res
; 13: 6207-6218, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34408488
Resultados
1 -
2
de 2
1
Próxima >
>>